These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 25141905)

  • 1. HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia.
    Jiamsakul A; Sungkanuparph S; Law M; Kantor R; Praparattanapan J; Li PC; Phanuphak P; Merati T; Ratanasuwan W; Lee CK; Ditangco R; Mustafa M; Singtoroj T; Kiertiburanakul S;
    J Int AIDS Soc; 2014; 17(1):19053. PubMed ID: 25141905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific.
    Ross J; Jiamsakul A; Kumarasamy N; Azwa I; Merati TP; Do CD; Lee MP; Ly PS; Yunihastuti E; Nguyen KV; Ditangco R; Ng OT; Choi JY; Oka S; Sohn AH; Law M
    HIV Med; 2021 Mar; 22(3):201-211. PubMed ID: 33151020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy.
    Geretti AM; Abdullahi A; Mafotsing Fopoussi O; Bonnett L; Fokom Defo V; Moudourou S; Fokam J; Kouanfack C; Torimiro J
    J Antimicrob Chemother; 2019 Oct; 74(10):3011-3015. PubMed ID: 31299067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.
    Johnston V; Cohen K; Wiesner L; Morris L; Ledwaba J; Fielding KL; Charalambous S; Churchyard G; Phillips A; Grant AD
    J Infect Dis; 2014 Mar; 209(5):711-20. PubMed ID: 23943851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
    Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
    De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
    BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa.
    Sigaloff KC; Hamers RL; Wallis CL; Kityo C; Siwale M; Ive P; Botes ME; Mandaliya K; Wellington M; Osibogun A; Stevens WS; van Vugt M; de Wit TF;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):23-31. PubMed ID: 21694603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chantratita W
    Curr HIV Res; 2008 Sep; 6(5):474-6. PubMed ID: 18855659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
    HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Prevalence of Drug Resistance Mutations Among Patients Failing First-Line Antiretroviral Therapy and Predictors of Virological Response 24 Weeks After Switch to Second-Line Therapy in São Paulo State, Brazil.
    Matsuda EM; Coelho LPO; Romero GF; de Moraes MJ; Lopez-Lopes GIS; Morejon K; Campeas AE; Cabral GB; Brígido LFM
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):156-164. PubMed ID: 28969448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High turnaround times and low viral resuppression rates after reinforced adherence counselling following a confirmed virological failure diagnostic algorithm in HIV-infected patients on first-line antiretroviral therapy from Tanzania.
    Kroidl A; Burger T; Urio A; Mugeniwalwo R; Mgaya J; Mlagalila F; Hoelscher M; Däumer M; Salehe O; Sangare A; Lennemann T; Maganga L
    Trop Med Int Health; 2020 May; 25(5):579-589. PubMed ID: 31984634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
    Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
    Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India.
    Karade SK; Ghate MV; Chaturbhuj DN; Kadam DB; Shankar S; Gaikwad N; Gurav S; Joshi R; Sane SS; Kulkarni SS; Kurle SN; Paranjape RS; Rewari BB; Gangakhedkar RR
    Medicine (Baltimore); 2016 Sep; 95(37):e4886. PubMed ID: 27631260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
    Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
    J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.
    Prasitsuebsai W; Teeraananchai S; Singtoroj T; Truong KH; Ananworanich J; Do VC; Nguyen LV; Kosalaraksa P; Kurniati N; Sudjaritruk T; Chokephaibulkit K; Kerr SJ; Sohn AH
    J Acquir Immune Defic Syndr; 2016 Aug; 72(4):380-6. PubMed ID: 27355415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.
    Shafran SD; Hughes CA
    HIV Med; 2023 Mar; 24(3):361-365. PubMed ID: 35973753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.
    Sigaloff KC; Kayiwa J; Musiime V; Calis JC; Kaudha E; Mukuye A; Matama C; Nankya I; Nakatudde L; Dekker JT; Hamers RL; Mugyenyi P; Rinke De Wit TF; Kityo C
    AIDS Res Hum Retroviruses; 2013 Jun; 29(6):925-30. PubMed ID: 23517497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral resistance following immunological monitoring in a resource-limited setting of western India: A cross-sectional study.
    Karade SK; Kulkarni SS; Ghate MV; Patil AA; Londhe R; Salvi SP; Kadam DB; Joshi RK; Rewari BB; Gangakhedkar RR
    PLoS One; 2017; 12(8):e0181889. PubMed ID: 28763465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.
    Aghokeng AF; Kouanfack C; Eymard-Duvernay S; Butel C; Edoul GE; Laurent C; Koulla-Shiro S; Delaporte E; Mpoudi-Ngole E; Peeters M
    J Int AIDS Soc; 2013 Jan; 16(1):18004. PubMed ID: 23374858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 drug resistance testing at second-line regimen failure in Arua, Uganda: avoiding unnecessary switch to an empiric third-line.
    Fily F; Ayikobua E; Ssemwanga D; Nicholas S; Kaleebu P; Delaugerre C; Pasquier E; Amoros Quiles I; Balkan S; Schramm B
    Trop Med Int Health; 2018 Oct; 23(10):1075-1083. PubMed ID: 30058269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.